Methods for enabling pet ownership
US-11641842-B2 · May 9, 2023 · US
US12012447B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12012447-B2 |
| Application number | US-202217731403-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 28, 2022 |
| Priority date | May 17, 2021 |
| Publication date | Jun 18, 2024 |
| Grant date | Jun 18, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present application provides compositions, methods, and systems for reducing allergic response to Fel D1. Such compositions, methods, and systems generally include a supplement comprising an anti-Fel D1 molecule and an animal digest.
Opening claim text (preview).
The invention is claimed as follows: 1. A supplement for reducing allergic response to Fel D1, the supplement comprising dried egg yolk powder comprising an anti-Fel D1 molecule that is anti-Fel D1-specific polyclonal immunoglobulin Y (sIgY), the supplement further comprising a dried animal digest that is thermally-treated meat-based enzymatic hydrolysate, the dried egg yolk powder is about 1 wt. % to about 30 wt. % of the supplement, the anti-Fel D1 molecule is about 0.0001 wt. % to about 1 wt. % of the supplement, and the dried animal digest is about 20 wt. % to about 80 wt. % of the supplement. 2. The supplement of claim 1 , further comprising an additive selected from the group consisting of vitamin E, vitamin C, and mixtures thereof. 3. A method of making a supplement for reducing allergic response to Fel D1, the method comprising: admixing (i) dried egg yolk powder comprising an anti-Fel D1 molecule that is anti-Fel D1-specific polyclonal immunoglobulin Y (sIgY) and (ii) a dried animal digest that is thermally-treated meat-based enzymatic hydrolysate, to form the supplement, the dried egg yolk powder is about 1 wt. % to about 30 wt. % of the supplement, the anti-Fel D1 molecule is about 0.0001 wt. % to about 1 wt. % of the supplement, and the dried animal digest is about 20 wt. % to about 80 wt. % of the supplement. 4. The method of claim 3 , further comprising admixing an additive selected from the group consisting of vitamin E, vitamin C, and mixtures thereof. 5. A system for reducing allergic response to Fel D1, comprising: a food composition, and a supplement, wherein the supplement comprises dried egg yolk powder comprising an anti-Fel D1 molecule that is anti-Fel D1-specific polyclonal immunoglobulin Y (sIgY), the supplement further comprising a dried animal digest that is thermally-treated meat-based enzymatic hydrolysate, the dried egg yolk powder is about 1 wt. % to about 30 wt. % of the supplement, the anti-Fel D1 molecule is about 0.0001 wt. % to about 1 wt. % of the supplement, and the dried animal digest is about 20 wt. % to about 80 wt. % of the supplement. 6. The system of claim 5 , wherein the food composition is a cat food. 7. A method for reducing allergic response to Fel D1, comprising: adding a supplement to a food composition, wherein the supplement comprises dried egg yolk powder comprising an anti-Fel D1 molecule that is anti-Fel D1-specific polyclonal immunoglobulin Y (sIgY), the supplement further comprising a dried animal digest that is thermally-treated meat-based enzymatic hydrolysate, the dried egg yolk powder is about 1 wt. % to about 30 wt. % of the supplement, the anti-Fel D1 molecule is about 0.0001 wt. % to about 1 wt. % of the supplement, the dried animal digest is about 20 wt. % to about 80 wt. % of the supplement; and administering the food composition to a cat. 8. The method of claim 7 , wherein administration is a regular administration.
Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid · CPC title
Vitamins · CPC title
from waste material, e.g. feathers, bones or skin (A23K10/24 takes precedence) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.